This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by Adistem Ltd.
Recruitment status was:  Recruiting
Information provided by:
Adistem Ltd Identifier:
First received: June 19, 2008
Last updated: June 28, 2008
Last verified: June 2008
The purpose of this study is to determine whether intravenous administration of autologous adipose stem cells is safe and beneficial in patients with type 1 diabetes.

Condition Intervention Phase
Type 1 Diabetes Mellitus Procedure: Autologous Adipose-derived Stem cells Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Intravenous Administration of Activated Autologous Adipose-Derived Stromal Vascular Fraction in Patients With Type 1 Diabetes

Resource links provided by NLM:

Further study details as provided by Adistem Ltd:

Primary Outcome Measures:
  • Lowering of insulin-dependence and anti-hyperglycemic medication dosages [ Time Frame: At 2, 4, 12, 24, 36, and 48 weeks ]

Secondary Outcome Measures:
  • Lowering of glycosylated hemoglobin (HbA1C). [ Time Frame: At 4, 12, 24, 36, and 48 weeks ]
  • Increased circulating C-Peptide levels [ Time Frame: At 4, 12, 24, 36, and 48 weeks. ]
  • Increased general well-being of patients. [ Time Frame: At 2, 4, 12, 24, 36, and 48 weeks. ]
  • No detrimental change seen in kidney function tests, liver function tests and other haematological parameters. [ Time Frame: At 2, 4, 12, 24, 36, and 48 weeks. ]

Estimated Enrollment: 30
Study Start Date: November 2007
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
This is the only arm and that is the treatment group.
Procedure: Autologous Adipose-derived Stem cells
Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
Other Name: Treatment Group

Detailed Description:
Diabetes Mellitus is of large epidemic proportions worldwide. It is proliferating at such a fast rate that new novel drugs and other therapeutic approaches are required. The purpose of this Phase I/II study is to determine whether the intravenous administration of activated adipose-derived stromal vascular fraction as a single procedure is safe and efficacious in patients with Type 1 Diabetes Mellitus. Patients will be observed over 12 months following the procedure, with 2 weeks, 1 month and tri-monthly diagnostics and life style questionaires.

Ages Eligible for Study:   16 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of Type I diabetes for at least 2 years
  • Insulin-dependent

Exclusion Criteria:

  • Presence of acute diabetic complications in the acute stage as recent myocardial infarction, recent CVA or acute renal failure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00703599

Contact: Letitia Lucero-Palma, MD 63-916-478-7512

Beverly Hills Medical Group Recruiting
Makati City, Manila, Philippines
Contact: Florencio Q Lucero, MD    63-917-896-6411   
Principal Investigator: Florencio Q Lucero, MD         
Veterens Memorial Medical Centre Recruiting
Quezon City, Manila, Philippines, 1229
Contact: Emerita A Barrenechea, MD    63-917-811-1008   
Principal Investigator: Emerita A Barrenechea, MD         
Sponsors and Collaborators
Adistem Ltd
Principal Investigator: Emeritta A Barrenechea, MD Veterens Memorial Medical Centre, Philippines
Principal Investigator: Florencio Q Lucero, MD University of Philippines, College of Medicine
Study Director: Letitia Lucero-Palma, MD Far Eastern University-NRMF Hospital, Quezon City, Philippines
Study Chair: Bill Paspaliaris, PhD Adistem Ltd, Hong Kong
  More Information

Responsible Party: Bill Paspaliaris / Director, Adistem Ltd Identifier: NCT00703599     History of Changes
Other Study ID Numbers: Ad-003
Study First Received: June 19, 2008
Last Updated: June 28, 2008

Keywords provided by Adistem Ltd:
Diabetes Mellitus
Adipose-derived stem cells
Adipose stromal vascular fraction

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 21, 2017